TheraRadar

Biotest

Pre-Approval PRO BETA
🔴

Stale Activity

No new clinical trials started in 2+ years. Activity may be declining or company may be focusing on existing programs. Last trial started: 9/9/2023

14
Total Trials
8
Phase 3
6
Phase 2
1
Recruiting
168
Score

Pipeline by Phase

Phase 3
8
Phase 2
6
Phase 1

Therapeutic Focus

Community-acquired Pneumonia Rheumatoid Arthritis Congenital Afibrinogenemia Congenital Hypofibrinogenemia Bleeding Disorder

Clinical Trials (14)

NCT05722938 Phase 3 RECRUITING

Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)

Started: 9/9/2023

NCT02065882 Phase 3 COMPLETED

Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency

Started: 3/1/2013

NCT03444324 Phase 3 COMPLETED

Adjusted Fibrinogen Replacement Strategy

Started: 4/3/2018

NCT05531149 Phase 3 TERMINATED

Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia

Started: 12/22/2022

NCT05170269 Phase 3 TERMINATED

Prevention of Maternal-fetal Cytomegalovirus Transmission After Primary Maternal Infection, GW ≤ 14 (PreCyssion)

Started: 11/17/2021

NCT02810444 Phase 3 COMPLETED

Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID

Started: 10/4/2016

NCT02859909 Phase 3 COMPLETED

This Clinical Study is to Test Efficacy and Safety of BT595 in Chronic Primary Immune Thrombocytopenia (ITP)

Started: 11/1/2016

NCT01856413 Phase 3 COMPLETED

A Clinical Trial of Zutectra in Patients Who Recently Received a Liver Transplant

Started: 12/1/2012

NCT04576728 Phase 2 COMPLETED

Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19

Started: 10/6/2020

NCT02554019 Phase 2 COMPLETED

Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus

Started: 9/28/2015

NCT01999192 Phase 2 TERMINATED

Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis

Started: 10/1/2013

NCT01420744 Phase 2 COMPLETED

Safety and Efficacy Study of BT086 to Evaluate Adjunctive Therapy in sCAP

Started: 8/1/2011

NCT01481493 Phase 2 COMPLETED

Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)

Started: 12/1/2010

NCT01072383 Phase 2 COMPLETED

Safety and Efficacy of Multiple Doses of BT061 in Patients With Moderate to Severe Chronic Plaque Psoriasis

Started: 2/1/2010

Drug Candidates

Trimodulin Placebo (human albumin 1%) BT524 (Part I) BT524 (Part II) BT524 FFP/Cryo BT097 IgG Next Generation (BT595) BT063 Placebo
Activity Status: Stale
Last Trial Started: 9/9/2023
Last Trial Ended: 5/5/2025
Trials (12 months): 0
Completed Trials: 10
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.